Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 15/20 | 0.65 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.53 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.49 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.49 |
| ▸ | RGS12 | O14924 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL1039135 | 1.00 | CHRM3 (0.65) | CHRM3CYP2D6CHRM2CHRM4CHRM5 | |
| Iodide SCHEMBL1042659 | 1.00 | CHRM3 (0.65) | CHRM3CYP2D6CHRM2CHRM4CHRM5 | |
| Iodide SCHEMBL1042706 | 0.99 | CHRM3 (0.64) | CHRM3CYP2D6CHRM2CHRM4CHRM5 | |
| SCHEMBL10147695 | 0.99 | CHRM3 (0.67) | CHRM3CYP2D6CHRM2CHRM4CHRM5 | |
| SCHEMBL10147593 | 0.99 | CHRM3 (0.67) | CHRM3CYP2D6CHRM2CHRM4CHRM5 | |
| SCHEMBL10147684 | 0.99 | CHRM3 (0.67) | CHRM3CYP2D6CHRM2CHRM4CHRM5 | |
| SCHEMBL10147680 | 0.98 | CHRM3 (0.65) | CHRM3CYP2D6CHRM2CHRM4CHRM5 | |
| Iodide SCHEMBL2902804 | 0.85 | CHRM3 (0.60) | CHRM3 | |
| SCHEMBL1037434 | 0.82 | CHRM3 (0.60) | CHRM3 | |
| SCHEMBL1037433 | 0.82 | CHRM3 (0.60) | CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130005695-A1 | QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2013-01-03 | — | — | US | disclosed |
| US-8207193-B2 | Quiniclidine derivatives of (hetero) arylcycloheptanecarboxylic acid as muscarinic receptor antagonists | ASTRAZENECA AB (SE) | 2012-06-26 | — | — | US | disclosed |
| EP-2094694-B1 | QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2011-01-26 | — | — | EP | disclosed |
| US-20100029713-A1 | QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029713-A1 | QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885CHRM1 2/4885CYP2D6 50/4885 |
| US-20130005695-A1 | QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885CHRM1 2/4885CYP2D6 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.